These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

619 related articles for article (PubMed ID: 9862678)

  • 1. Cytotoxic T cell responses to DNA vaccination: dependence on antigen presentation via class II MHC.
    Maecker HT; Umetsu DT; DeKruyff RH; Levy S
    J Immunol; 1998 Dec; 161(12):6532-6. PubMed ID: 9862678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
    Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
    Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Priming MHC-I-restricted cytotoxic T lymphocyte responses to exogenous hepatitis B surface antigen is CD4+ T cell dependent.
    Wild J; Grusby MJ; Schirmbeck R; Reimann J
    J Immunol; 1999 Aug; 163(4):1880-7. PubMed ID: 10438922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway.
    Rock KL; Clark K
    J Immunol; 1996 May; 156(10):3721-6. PubMed ID: 8621907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intradermal injections of polyarginine-containing immunogenic antigens preferentially elicit Tc1 and Th1 activation and antitumour immunity.
    Mitsui H; Okamoto T; Kanzaki M; Inozume T; Shibagaki N; Shimada S
    Br J Dermatol; 2010 Jan; 162(1):29-41. PubMed ID: 19863514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Active CD4+ helper T cells directly stimulate CD8+ cytotoxic T lymphocyte responses in wild-type and MHC II gene knockout C57BL/6 mice and transgenic RIP-mOVA mice expressing islet beta-cell ovalbumin antigen leading to diabetes.
    Ye Z; Ahmed KA; Hao S; Zhang X; Xie Y; Munegowda MA; Meng Q; Chibbar R; Xiang J
    Autoimmunity; 2008 Nov; 41(7):501-11. PubMed ID: 18855194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced CTL response by controlled intracellular trafficking of antigen in dendritic cells following DNA vaccination.
    Isaji K; Kawase A; Matono M; Guan X; Nishikawa M; Takakura Y
    J Control Release; 2009 May; 135(3):227-33. PubMed ID: 19331843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization.
    Bristol JA; Orsini C; Lindinger P; Thalhamer J; Abrams SI
    Cell Immunol; 2000 Nov; 205(2):73-83. PubMed ID: 11104579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a novel Hsp70-based DNA vaccine as a multifunctional antigen delivery system.
    Yamaoka A; Guan X; Takemoto S; Nishikawa M; Takakura Y
    J Control Release; 2010 Mar; 142(3):411-5. PubMed ID: 19913062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene.
    Rowe HM; Lopes L; Ikeda Y; Bailey R; Barde I; Zenke M; Chain BM; Collins MK
    Mol Ther; 2006 Feb; 13(2):310-9. PubMed ID: 16275163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cytotoxic T lymphocyte response against a protein antigen does not decrease the antibody response to that antigen although antigen-pulsed B cells can be targets.
    Wang W; Golding B
    Immunol Lett; 2005 Sep; 100(2):195-201. PubMed ID: 15916814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
    Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
    Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitization of MHC class I-restricted T cells to exogenous proteins: evidence for an alternative class I-restricted antigen presentation pathway.
    Martinez-Kinader B; Lipford GB; Wagner H; Heeg K
    Immunology; 1995 Oct; 86(2):287-95. PubMed ID: 7490131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4+ TH1 cells generated by Ii-PADRE DNA at prime phase are important to induce effectors and memory CD8+ T cells.
    Park JY; Jin DH; Lee CM; Jang MJ; Lee SY; Shin HS; Chung YH; Kim KY; Kim SS; Lee WB; Shin YK; Lee WJ; Park YM; Kim D
    J Immunother; 2010 Jun; 33(5):510-22. PubMed ID: 20463596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.
    De Veerman M; Heirman C; Van Meirvenne S; Devos S; Corthals J; Moser M; Thielemans K
    J Immunol; 1999 Jan; 162(1):144-51. PubMed ID: 9886380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of class I MHC-restricted, peptide-specific cytolytic T lymphocytes by peptide priming in vivo.
    Ishioka GY; Colon S; Miles C; Grey HM; Chesnut RW
    J Immunol; 1989 Aug; 143(4):1094-100. PubMed ID: 2787356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CpG-DNA aided cross-presentation of soluble antigens by dendritic cells.
    Maurer T; Heit A; Hochrein H; Ampenberger F; O'Keeffe M; Bauer S; Lipford GB; Vabulas RM; Wagner H
    Eur J Immunol; 2002 Aug; 32(8):2356-64. PubMed ID: 12209649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovalbumin injected with complete Freund's adjuvant stimulates cytolytic responses.
    Ke Y; Li Y; Kapp JA
    Eur J Immunol; 1995 Feb; 25(2):549-53. PubMed ID: 7875219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of tumor-specific cytotoxic T lymphocyte and prolongation of the survival of tumor-bearing mice using interleukin-18-secreting fibroblasts loaded with an epitope peptide.
    Chung SW; Cohen EP; Kim TS
    Vaccine; 2004 Jun; 22(20):2547-57. PubMed ID: 15193380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.